Skip to main content
. Author manuscript; available in PMC: 2016 Aug 1.
Published in final edited form as: Nat Rev Gastroenterol Hepatol. 2015 Jun 30;12(8):437–445. doi: 10.1038/nrgastro.2015.97

Figure 1.

Figure 1

Viral load decay in a patient with genotype 1 HCV treated with 15 MIU daily of IFN-α. a) Viral decline during the first 2 days of therapy as predicted by Equation 2 (solid line) plotted alongside actual data (solid circles). b) Viral decline in the same patient over the first 10 days of therapy (solid circles) and the best-fit of the Neumann et al. model6 that incorporates a second phase decline and the death of infected cells (solid line). Adapted from Neumann et al. Science 282: 103–107 (1998).